Literature DB >> 8314475

High dose interferon treatment in chronic hepatitis C.

S Iino1.   

Abstract

One hundred and twenty six patients were enrolled in a study to assess the effect of different interferon alfa-2b treatment regimens on the rate of increase in alanine aminotransferase (ALT) activities after treatment. Results indicated that a high daily dosage of interferon (10 million units (MU)) given six times a week for two weeks followed by 12 weeks of thrice weekly dosing was more effective at producing sustained normal ALT values than either eight weeks of 10 MU interferon six times a week or four weeks of 10 MU six times a week followed by eight weeks of thrice weekly dosing. Multiple regression analysis of clinical parameters before treatment showed that the outcome was dependent upon treatment group (p < 0.001) and the initial hepatitis C virus (HCV)-RNA value (p < 0.05). Anti-HCV titre and liver histology had a considerable but not significant effect on the response to treatment. The most frequently observed side effect was flu like syndrome, which occurred in over 90% of patients. In addition, 21% of patients experienced some degree of hair loss. Treatment was stopped because of side effects in 11 of 126 (9%) patients, evenly distributed between the three groups.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314475      PMCID: PMC1374031          DOI: 10.1136/gut.34.2_suppl.s114

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

2.  Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

Authors:  F Tinè; S Magrin; A Craxì; L Pagliaro
Journal:  J Hepatol       Date:  1991-09       Impact factor: 25.083

3.  Clinical significance of anti-IFN-alpha antibody titres during interferon therapy.

Authors:  P von Wussow; M Freund; B Block; H Diedrich; H Poliwoda; H Deicher
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

6.  Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.

Authors:  P Marcellin; N Boyer; E Giostra; C Degott; A M Courouce; F Degos; H Coppere; P Cales; P Couzigou; J P Benhamou
Journal:  Hepatology       Date:  1991-03       Impact factor: 17.425

7.  Interferon-induced chronic active hepatitis?

Authors:  M O Silva; K R Reddy; L J Jeffers; M Hill; E R Schiff
Journal:  Gastroenterology       Date:  1991-09       Impact factor: 22.682

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.

Authors:  H Okamoto; S Okada; Y Sugiyama; T Tanaka; Y Sugai; Y Akahane; A Machida; S Mishiro; H Yoshizawa; Y Miyakawa
Journal:  Jpn J Exp Med       Date:  1990-08

10.  Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon.

Authors:  P Burman; T H Tötterman; K Oberg; F A Karlsson
Journal:  J Clin Endocrinol Metab       Date:  1986-11       Impact factor: 5.958

  10 in total
  4 in total

1.  The Effect Of Long Term and High Dose Interferon Treatment In Chronic Hepatitis C.

Authors:  Gábor Horváth; Gyula Stotz; Gyula Tolvaj; Henrik Osztrogonácz; Károly Dávid
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

Authors:  Kimberley J Smith; Suzanne Norris; Cliona O'Farrelly; Shane M O'Mara
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

4.  Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.

Authors:  Akira Sato; Masahiro Yamauchi; Takayuki Yamada; Reiko Kumano; Kayo Adachi; Toshiya Ishii; Mikihito Hayashi; Daisuke Kumon
Journal:  Clin J Gastroenterol       Date:  2014-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.